Person:
MUTLU GENÇKAL, HASENE

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

MUTLU GENÇKAL

First Name

HASENE

Name

Filters

20221
Reset filters

Settings

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Publication
    The mechanism for anticancer and apoptosis-inducing properties of cu(ii) complex with quercetin and 1,10-phenanthroline
    (Wiley-v C H Verlag Gmbh, 2022-10-13) Cevatemre, Buse; Ari, Ferda; ARI, FERDA; Done, Gülseven; Akgün, Oğuzhan; Akgün, Halime; Gençkal, Hasene Mutlu; MUTLU GENÇKAL, HASENE; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Biyoloji Bölümü.; Bursa Uludağ Üniversitesi/Fen Edebiyat Fakültesi/Kimya Bölümü.; 0000-0002-6729-7908; 0000-0002-8410-1786; 0000-0002-2048-3252; 0000-0002-0026-7755; AAG-7012-2021; A-5608-2019
    This article covers the anticancer activities and mechanisms of action of Cu(II) complexes of flavonoid-derived quercetin and 1,10-phenanthroline ligands. The antiproliferative activity of the complex and its ligands was evaluated by MTT, ATP, and SRB viability assays in human lung cancer cells (A549, H1299). Findings for apoptosis were determined by fluorescent staining, flow cytometry analysis, and the M30 antigen method. In addition, the mechanism of action of the complex was investigated by Annexin V staining, caspase 3/7 activity, ROS formation, and cell cycle analysis. The involvement of caspases, thus, apoptosis was confirmed by rescuing cell death by using a pan-caspase inhibitor (Z-VAD-FMK). Again, increased ROS levels in the cell showed that death may occur by apoptosis. For this reason, the accuracy of ROS-induced apoptosis in cells has been proven as a result of the application of N-acetylcysteine (NAC), which is a ROS inhibitor. The efficacy of the complex was compared with Cisplatin and ligands. The results showed that the Cu(II) flavonoid complex is cytotoxic on lung cancer cells and may have the potential to act as an effective metal-based anticancer drug with a lower IC50 over Cisplatin.